Our study demonstrated that Sal exerts antiangiogenic activity in vitro and in vivo through blocking VEGFR2/STAT3 pathway in endothelial cells, suggesting that STAT3 is a potential target of Sal in gastric cancer cells. The gene discussed is STAT3; the disease is gastric cancer.